What the evidence says. Conflicting results across studies; benefit uncertain.
What is BHA & BHT?
BHA & BHT (E320 / E321) is a sweetener or food additive used for potent lipid antioxidant: interrupts free-radical chain oxidation of unsaturated fats, preventing rancidity and off-flavors. NutriDex grades the human evidence as Mixed. BHA (E320, butylated hydroxyanisole) and BHT (E321, butylated hydroxytoluene) are synthetic phenolic antioxidants added to fat-containing foods to prevent oxidative rancidity. Both are approved across major jurisdictions: FDA treats them as GRAS / approved food additives and EFSA re-evaluated both (2011/2012), setting acceptable daily intakes and concluding neither is genotoxic at use levels. The principal controversy is carcinogenicity: high-dose dietary BHA causes forestomach tumors in rodents, leading IARC to classify it Group 2B (possibly carcinogenic) and NTP to list it as "reasonably anticipated to be a human carcinogen," though the rodent forestomach mechanism is widely judged not relevant to humans (who lack a forestomach). BHT is IARC Group 3 (not classifiable), with mixed animal data. Human evidence of harm at dietary exposures is essentially absent, but in 2026 the FDA opened a formal reassessment of BHA.
Purported Benefits
✓Potent lipid antioxidant: interrupts free-radical chain oxidation of unsaturated fats, preventing rancidity and off-flavors
✓Extends shelf life of fats, oils, and fat-containing dry/processed foods
✓Heat-stable, so it survives frying, baking, and high-temperature processing (carry-through antioxidant)
✓Protects fat-soluble vitamins (A, E) and color/aroma compounds from oxidative degradation
✓Often used at very low concentrations (typically <=200 ppm of fat), frequently combined with each other or with TBHQ/gallates for synergy
✓Also used in food packaging, animal feed, cosmetics, and pharmaceuticals as a stabilizer
Dosing & Compounds
Typical Dose
FDA: GRAS / approved food additives (BHA affirmed GRAS 1958, approved as additive 1961; both limited under 21 CFR, typically to ~0.02% of fat/oil content). EFSA acceptable daily intakes: BHA 1.0 mg/kg body weight/day (2011 re-evaluation); BHT 0.25 mg/kg bw/day (2012 re-evaluation). JECFA: BHA group ADI 0-0.5 mg/kg bw/day; BHT ADI 0-0.3 mg/kg bw/day. California Proposition 65 has listed BHA as a chemical "known to cause cancer" since 1990 (BHT is not listed). In February 2026 the FDA opened a formal request-for-information reassessment of BHA, with BHT and azodicarbonamide flagged for subsequent review.
Active Compounds
BHA = E320 / INS 320 (CAS 25013-16-5); BHT = E321 / INS 321 (CAS 128-37-0)Found in: vegetable oils and shortening, butter/margarine, breakfast cereals, snack foods, chips and crackers, nuts, chewing gum, dehydrated potatoes, cured/processed meats, instant mashed potatoes, baked goods, and candyCommon on labels as 'BHA', 'BHT', 'butylated hydroxyanisole', or 'butylated hydroxytoluene', often 'to preserve freshness' or 'added to protect flavor'Also widely used outside food: cereal/snack packaging liners, animal feed, cosmetics and personal-care products, and as a stabilizer in some medicines and supplements
Safety & Cautions
⚠
At dietary exposures (which are typically far below the ADIs), neither BHA nor BHT is genotoxic, and EFSA concluded any carcinogenic potential would be thresholded and not of concern at the ADI. The strongest documented harm is in rodents fed very high doses: BHA induces benign and malignant forestomach tumors (papillomas/squamous-cell carcinomas) in rats, mice, and hamsters — the basis for IARC Group 2B and NTP's "reasonably anticipated to be a human carcinogen" listing. An IARC workshop and most toxicologists judge this forestomach mechanism (local irritation/hyperplasia in a non-glandular stomach compartment humans do not possess) to have limited relevance to human dietary exposure. BHT shows mixed/inconsistent animal data (variously acting as tumor promoter, inhibitor, or neither; high doses linked to liver and lung effects and hemorrhagic effects in susceptible species), and IARC places it in Group 3. There is no robust human evidence of cancer or other harm at food-relevant intakes; large-cohort biomonitoring of food-additive mixtures (e.g., NutriNet-Sante) is ongoing. Some individuals report contact/allergic skin reactions. People wanting to minimize exposure can choose products labeled BHA/BHT-free, but the population-level risk from dietary use is considered low. Educational only — always check with your doctor or pharmacist before combining BHA & BHT with any medicine.
BHA & BHT is most often taken for Potent lipid antioxidant: interrupts free-radical chain oxidation of unsaturated fats, preventing rancidity and off-flavors, Extends shelf life of fats, oils, and fat-containing dry/processed foods, Heat-stable, so it survives frying, baking, and high-temperature processing (carry-through antioxidant), Protects fat-soluble vitamins (A, E) and color/aroma compounds from oxidative degradation. Synthetic phenolic antioxidants that keep fats from going rancid
Does BHA & BHT work — what does the evidence say?
Mixed evidence. Conflicting results across studies; benefit uncertain. BHA (E320, butylated hydroxyanisole) and BHT (E321, butylated hydroxytoluene) are synthetic phenolic antioxidants added to fat-containing foods to prevent oxidative rancidity. Both are approved across major jurisdictions: FDA treats them as GRAS / approved food additives and EFSA re-evaluated both (2011/2012), setting acceptable daily intakes and concluding neither is genotoxic at use levels. The principal controversy is carcinogenicity: high-dose dietary BHA causes forestomach tumors in rodents, leading IARC to classify it Group 2B (possibly carcinogenic) and NTP to list it as "reasonably anticipated to be a human carcinogen," though the rodent forestomach mechanism is widely judged not relevant to humans (who lack a forestomach). BHT is IARC Group 3 (not classifiable), with mixed animal data. Human evidence of harm at dietary exposures is essentially absent, but in 2026 the FDA opened a formal reassessment of BHA.
What is the typical dose of BHA & BHT?
FDA: GRAS / approved food additives (BHA affirmed GRAS 1958, approved as additive 1961; both limited under 21 CFR, typically to ~0.02% of fat/oil content). EFSA acceptable daily intakes: BHA 1.0 mg/kg body weight/day (2011 re-evaluation); BHT 0.25 mg/kg bw/day (2012 re-evaluation). JECFA: BHA group ADI 0-0.5 mg/kg bw/day; BHT ADI 0-0.3 mg/kg bw/day. California Proposition 65 has listed BHA as a chemical "known to cause cancer" since 1990 (BHT is not listed). In February 2026 the FDA opened a formal request-for-information reassessment of BHA, with BHT and azodicarbonamide flagged for subsequent review.
Is BHA & BHT safe? Any cautions or side effects?
At dietary exposures (which are typically far below the ADIs), neither BHA nor BHT is genotoxic, and EFSA concluded any carcinogenic potential would be thresholded and not of concern at the ADI. The strongest documented harm is in rodents fed very high doses: BHA induces benign and malignant forestomach tumors (papillomas/squamous-cell carcinomas) in rats, mice, and hamsters — the basis for IARC Group 2B and NTP's "reasonably anticipated to be a human carcinogen" listing. An IARC workshop and most toxicologists judge this forestomach mechanism (local irritation/hyperplasia in a non-glandular stomach compartment humans do not possess) to have limited relevance to human dietary exposure. BHT shows mixed/inconsistent animal data (variously acting as tumor promoter, inhibitor, or neither; high doses linked to liver and lung effects and hemorrhagic effects in susceptible species), and IARC places it in Group 3. There is no robust human evidence of cancer or other harm at food-relevant intakes; large-cohort biomonitoring of food-additive mixtures (e.g., NutriNet-Sante) is ongoing. Some individuals report contact/allergic skin reactions. People wanting to minimize exposure can choose products labeled BHA/BHT-free, but the population-level risk from dietary use is considered low.
How many studies support BHA & BHT?
NutriDex cites 8 sources for BHA & BHT, graded "Mixed".
Cite this page
APA
Peh, D. (2026). BHA & BHT (E320 / E321): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 16 Sept 2026, from https://nutridex.info/s/bha-bht
BibTeX
@misc{nutridex_bha_bht,
author = {Peh, Daryl},
title = {BHA \& BHT (E320 / E321): Benefits, Dosage, Side Effects \& Evidence},
year = {2026},
howpublished = {NutriDex --- The Supplement Research Compendium},
url = {https://nutridex.info/s/bha-bht},
note = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-09-16}
}
For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.